Beijing Institute of New Medicine

Beijing Institute of New Medicine (BINM) is a prominent pharmaceutical research and development institution based in Beijing, China, and a subsidiary of the China State Institute of Pharmaceutical Industry (CSIPI) under the China National Pharmaceutical Group (Sinopharm). Founded in 1987, BINM specializes in the discovery and development of new chemical entities, traditional Chinese medicines, and advanced pharmaceutical formulations. The institute offers a comprehensive suite of R&D services, including drug synthesis, pharmacological evaluation, and quality control, serving as a vital link between laboratory research and industrial-scale production. BINM has successfully brought numerous products to market, with a particular focus on therapeutic areas such as anti-infectives, cardiovascular health, and oncology. As a state-level high-tech enterprise, it plays a significant role in advancing the pharmaceutical innovation landscape within the Sinopharm ecosystem and the broader Chinese healthcare sector.